The Team at Newcastle Helix are celebrating after winning the ‘Collaborators Award’ in the EG
Q&A: Iksuda Therapeutics: Leading the way on helping to advance care for ovarian and lung cancer patients
We talk to David Simpson, CEO at Iksuda Therapeutics about what they do, how
Biosphere tenant Iksuda Therapeutics presents first data on lead antibody drug conjugate, demonstrating effective tumour regression.
Iksuda Therapeutics (Iksuda), a developer of next generation Antibody Drug Conjugates (ADCs), today announced
Atelerix is a spin out from Newcastle University and pioneers in the storage and
The Biosphere has been recognised for outstanding levels of support to companies in the